Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Andreas Trumpp

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6212-3466; OpenAlex author ID A5081577791. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
100
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 17

  1. Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC. Co-author DOI 10.1097/mpa.0000000000002553↗
  2. Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer. Co-author DOI 10.1038/s41467-024-55330-7↗
  3. Characterization of single neurons reprogrammed by pancreatic cancer. Last author DOI 10.1038/s41586-025-08735-3↗
  4. Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancer. Co-author DOI 10.1136/jitc-2025-011802↗
  5. HAPLN1 potentiates peritoneal metastasis in pancreatic cancer. Co-author DOI 10.1038/s41467-023-38064-w↗
  6. Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients w… Co-author DOI 10.1111/cts.13661↗
  7. Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype. Co-author DOI 10.1136/gutjnl-2021-326550↗
  8. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer. Co-author DOI 10.1172/jci.insight.154475↗
  9. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Co-author DOI 10.1038/s43018-021-00258-w↗
  10. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Last author DOI 10.1053/j.gastro.2021.04.082↗
  11. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  12. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrosp… Co-author DOI 10.1016/j.pan.2017.04.012↗
  13. Survival of pancreatic cancer cells lacking KRAS function. Co-author DOI 10.1038/s41467-017-00942-5↗
  14. Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000743↗
  15. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.4038↗
  16. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2016.1240859↗
  17. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/cdd.2014.217↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Martin Ronald Sprick · 11 shared papers, 2015–2026 · strength 1.14
  2. Elisa Espinet Espinet · 8 shared papers, 2016–2025 · strength 0.89
  3. Thilo Hackert · 4 shared papers, 2016–2026 · strength 0.49
  4. Shiv K. Singh · 4 shared papers, 2021–2025 · strength 0.49
  5. Elisabeth Heßmann · 4 shared papers, 2021–2025 · strength 0.49
  6. Volker Ellenrieder · 4 shared papers, 2021–2025 · strength 0.49
  7. Rienk Offringa · 3 shared papers, 2016–2025 · strength 0.43
  8. Albrecht Stenzinger · 4 shared papers, 2016–2025 · strength 0.42
  9. Vera Thiel · 2 shared papers, 2025–2026 · strength 0.41
  10. Elisa M. Noll · 4 shared papers, 2016–2026 · strength 0.40
  11. Uday Kishore · 3 shared papers, 2021–2025 · strength 0.40
  12. Lukas Klein · 3 shared papers, 2021–2025 · strength 0.40
  13. Mengyu Tu · 3 shared papers, 2021–2025 · strength 0.40
  14. Jens Thomas Siveke · 3 shared papers, 2021–2023 · strength 0.37
  15. Christoph Roesli · 3 shared papers, 2016–2026 · strength 0.34
  16. Niklas Krebs · 2 shared papers, 2022–2025 · strength 0.30
  17. Laura Kuhlmann · 2 shared papers, 2017–2026 · strength 0.30
  18. Oliver Strobel · 3 shared papers, 2016–2025 · strength 0.30
  19. Argyris Papantonis · 2 shared papers, 2021–2025 · strength 0.28
  20. Laura Urbach · 2 shared papers, 2021–2025 · strength 0.28
  21. Nathalia A. Giese · 2 shared papers, 2016–2026 · strength 0.27
  22. Dirk Jäger · 3 shared papers, 2017–2023 · strength 0.27
  23. Christoph Springfeld · 3 shared papers, 2017–2023 · strength 0.27
  24. Michael Volkmar · 2 shared papers, 2016–2025 · strength 0.26
  25. Isabel C. Poschke · 2 shared papers, 2016–2025 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.